Form 4: IDEAYA CMO Granted 175,000 Stock Options

IDEAYA Biosciences' Chief Medical Officer, Darrin Beaupre, was granted 175,000 stock options with an exercise price of $32.19, vesting over four years.

Summary

• Darrin Beaupre, Chief Medical Officer of IDEAYA Biosciences, Inc. (IDYA), was granted 175,000 stock options.
• The stock options have an exercise price of $32.19 per share.
• The transaction date for this grant was January 30, 2026.
• The options are set to expire on January 30, 2036.
• Vesting commences on January 1, 2026, with 25% of the shares vesting on the first anniversary (January 1, 2027).
• Following the initial 25% vesting, 1/48th of the total shares will vest monthly thereafter.
• The options will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, which is January 1, 2030.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development, reflecting standard executive compensation practices aimed at aligning management incentives with long-term shareholder value.

Positives

• The grant of 175,000 stock options to the Chief Medical Officer aligns management's interests with shareholder value creation.
• The four-year vesting schedule encourages long-term commitment and performance from a key executive.

Negatives

• NA

Risks

• NA

Future Outlook

The vesting schedule for the stock options indicates a long-term incentive structure for the Chief Medical Officer, suggesting an expectation of continued service and contribution to the company's future performance over the next four years.

Management Comments

• NA

Industry Context

StockSavvy.ai notes that granting stock options to key executives like the Chief Medical Officer is a standard practice in the biotechnology and pharmaceutical industries to attract, retain, and incentivize top talent, aligning their long-term interests with shareholder value creation. This is particularly common in growth-oriented companies like IDEAYA Biosciences, where future drug development and commercialization success are critical.

Comparison to Industry Standards

• The grant of 175,000 stock options to a Chief Medical Officer represents a significant incentive package, comparable to those offered by other mid-cap biotechnology companies for key executive roles.
• The four-year vesting schedule, including a one-year cliff and monthly vesting thereafter, is a common industry standard designed to promote long-term retention and performance.
• The exercise price of $32.19, likely the market price on the grant date, is typical for at-the-money option grants in executive compensation.

Management Changes

Corporate Governance

Legal Proceedings

• NA

Related Party Transactions

• Grant of 175,000 stock options to Darrin Beaupre, Chief Medical Officer, as part of his compensation package.

Stakeholder Impact

• Shareholders: Potential for increased shareholder value if the options incentivize strong executive performance, balanced against potential future dilution if options are exercised.
• Management: Darrin Beaupre's compensation package is enhanced, aligning his financial interests more closely with the company's stock performance.

Next Steps

• Continued service and performance by the Chief Medical Officer to meet the vesting conditions of the options.
• Potential future exercise of options by Darrin Beaupre once vested and if the stock price is above the exercise price.

Key Dates

Recommendation

This Form 4 filing reports a routine executive compensation event (stock option grant) and does not provide new information that would fundamentally alter the investment thesis for IDEAYA Biosciences. While it aligns management incentives, it's not a catalyst for a 'buy' or 'sell' recommendation. Investors should continue to hold based on the company's underlying fundamentals and pipeline progress.

Keywords

IDEAYA Biosciences, IDYA, Darrin Beaupre, stock options, insider transaction, Form 4, executive compensation, beneficial ownership